Investigating how the Hippo pathway affects scleroderma development
Official title: Role of the Hippo pathway in scleroderma pathogenesis
Funded at University of Michigan at Ann Arbor · NIH-11013342 · Data updated 2026-11-12
This study is looking at how a specific cell signaling pathway might be involved in scleroderma, a condition that thickens the skin and can impact other organs, to help find new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 19, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $583,594 |
| NIH project number | 5R01AI183620-02 |
| Project ID | NIH-11013342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with scleroderma, particularly those experiencing significant skin and organ involvement.
✕Less likely to help
Patients with scleroderma who are not actively experiencing symptoms or those with other unrelated autoimmune conditions may not benefit from this research.
What this research studies
This research focuses on understanding the role of the Hippo signaling pathway in the development of scleroderma, a disease that causes thickening of the skin and can affect internal organs. By utilizing advanced techniques like single-cell sequencing, the researchers aim to explore how specific cells interact and contribute to the fibrosis seen in scleroderma. The study will investigate the mechanisms behind these cellular changes and how they relate to the disease's progression, potentially leading to new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or even reverse the effects of scleroderma.
How similar studies have gone: Previous research has shown promising results in understanding the role of signaling pathways in autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Gudjonsson, Johann Eli — University of Michigan at Ann Arbor
- Study coordinator: Gudjonsson, Johann Eli
Related research
Other NIH-funded projects on the same topics.
-
Angiogenesis imaging in scleroderma to track digital ulcers
A patient-friendly look at using a special imaging tracer to watch blood vessel growth in the hands of people with scleroderma to help manage digital ulcers.
-
Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma
A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.
-
Pediatric Scleroderma: Mapping Cells and Tissues to Personalize Care
A study will map the different cell types and tissue patterns in skin from children with scleroderma to identify patient-specific disease subtypes that could guide targeted therapies.
-
CD38 and NAD metabolism in scleroderma (systemic sclerosis) fibrosis
This grant explores how changes in NAD metabolism related to CD38 and NNMT may drive scarring in systemic sclerosis and tests new ways to stop it.
-
ISG15-positive monocytes and SPP1 macrophages in scleroderma lung disease
This grant studies a specific immune cell pathway in systemic sclerosis with lung scarring to help predict how the disease progresses.
-
Autoantibodies define scleroderma subgroups with distinct cancer links
Researchers are studying how specific autoantibodies in scleroderma patients relate to cancer timing and risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.